2115. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.
As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws.
2116. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
作者: Penny F Whiting.;Robert F Wolff.;Sohan Deshpande.;Marcello Di Nisio.;Steven Duffy.;Adrian V Hernandez.;J Christiaan Keurentjes.;Shona Lang.;Kate Misso.;Steve Ryder.;Simone Schmidlkofer.;Marie Westwood.;Jos Kleijnen.
来源: JAMA. 2015年313卷24期2456-73页
Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear.
2117. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
作者: Stacy Loeb.;Yasin Folkvaljon.;Mats Lambe.;David Robinson.;Hans Garmo.;Christian Ingvar.;Pär Stattin.
来源: JAMA. 2015年313卷24期2449-55页
The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development of malignant melanoma. An increased risk of melanoma in sildenafil users was recently reported.
2118. Association Between Early Screening for Patent Ductus Arteriosus and In-Hospital Mortality Among Extremely Preterm Infants.
作者: Jean-Christophe Rozé.;Gilles Cambonie.;Laetitia Marchand-Martin.;Veronique Gournay.;Xavier Durrmeyer.;Mélanie Durox.;Laurent Storme.;Raphael Porcher.;Pierre-Yves Ancel.; .
来源: JAMA. 2015年313卷24期2441-8页
There is currently no consensus for the screening and treatment of patent ductus arteriosus (PDA) in extremely preterm infants. Less pharmacological closure and more supportive management have been observed without evidence to support these changes.
2119. Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction.
作者: Sean D Pokorney.;Amy L Miller.;Anita Y Chen.;Laine Thomas.;Gregg C Fonarow.;James A de Lemos.;Sana M Al-Khatib.;Eric D Peterson.;Tracy Y Wang.
来源: JAMA. 2015年313卷24期2433-40页
Implantable cardioverter-defibrillators (ICDs) are not recommended within 40 days of myocardial infarction (MI); thus, ICD implantation might not be considered during the post-MI care transition.
|